

1 Prevalence of Hyperglycemia in Pregnancy using early, standard and late screening: a
2 study in the Primary Care Health in Lima, Peru

3

4 Authors

5

6 S.N. Seclén ¹ (ORCID: 0000-0002-2431-099X)

7 Lucy Nelly Damas-Casani ² (ORCID : 0000-0002-8714-2217)

8 Vicky Delia Cecilia Motta-Montoya ¹

9 Sandra Lesly Jiménez-Martel ^{1,3}

10 Marlon Yovera-Aldana ⁴. (ORCID: 0000-0002-1947-7736)

11

12 Affiliations

13 1 Universidad Peruana Cayetano Heredia, Lima, Perú

14 2 Endocrinology Service, Hospital María Auxiliadora, Lima, Perú

15 3 Endocrinology Service, Hospital Santa Rosa, Lima, Perú

16 4 Grupo de Investigación de Neurociencias, Metabolismo y Efectividad clínica y

17 Sanitaria, Universidad Científica del Sur, Lima , Perú

18

19 **Corresponding author**

20 E-mail: myovera@cientifica.edu.pe (MYA)

21 **Abstract**

22 **Objective:** To determine the prevalence of hyperglycemia in pregnancy (HIP) based on
23 the timing of screening in pregnant women.

24 **Materials and Methods:** A cross-sectional study was conducted on pregnant women
25 recruited from February 2019 to August 2022 in four primary care centers in Lima,
26 excluding those with known diabetes. Screening involved an Oral Glucose Tolerance Test
27 with 75 g of glucose at the first contact. It was classified as early if performed before 24
28 weeks, standard between 24-28 weeks, and late if after 29 weeks. For gestational diabetes
29 mellitus (GDM), we used the IADPSG diagnostic criteria for any gestational age. For
30 diabetes in pregnancy (DIP), glucose levels over 126 mg/dl fasting or over 200 mg/dl at
31 2 hours post-load were used. We calculated prevalence ratios for GDM and DIP based on
32 the type of screening.

33 **Results:** We included 4,495 pregnant women with an average age of 29 years. The
34 prevalence of HIP was 14.9%, GDM was 14.2%, and DIP was 0.7%. Early GDM
35 screening showed a 23% higher prevalence compared to GDM screening at 24-28 weeks,
36 adjusted for age (PR 1.23; 95% CI 1.01 – 1.49; p=0.036). No differences were found for
37 DIP across screening types.

38 **Conclusion:** In pregnant women at four primary centers in Lima, one in seven pregnant
39 women (14.9%) had HIP, GDM was 14.2%, and DIP was 0.7%.. Early screening showed
40 the highest proportion of GDM compared to standard or late screening. Longitudinal
41 studies are needed to validate whether this higher early prevalence impacts maternal-
42 perinatal complications.

43 Key words (MeSH) : Diabetes, gestacional; mass screening; prevalence study; glucose
44 tolerance test; Peru;

45 **Introducción**

46 Globally, approximately 16.7% of pregnancies present hyperglycemia in pregnancy
47 (HIE), defined as any known pre-existing alteration or first diagnosed during gestation.
48 Of these cases, 80.3% are due to gestational diabetes mellitus (GDM). The prevalence of
49 HIE progressively increases with age and 80% originating in low- to middle-income
50 countries where access to healthcare is limited. [1] HIE is associated with maternal and
51 perinatal complications. [2] Normalizing blood glucose levels in patients with GDM and
52 diabetes in pregnancy (DIP) through lifestyle changes, and in some cases
53 pharmacological treatment, has been shown to reduce maternal-perinatal complications
54 by more than 60%. [3]

55 In the last two decades, the increase in the prevalence of GDM has ranged from 16% to
56 127%. This is attributed to the progressive rise in obesity by unhealthy lifestyles, greater
57 governmental efforts to conduct universal screening and a diagnostic threshold criteria
58 diminished[4]. In Peru, the prevalence of overweight and obesity in women of
59 reproductive age is 37% and 28%, respectively[5]. Consequently, nearly 50% of pregnant
60 women have excess weight in the first trimester, making it one of the main risk factors
61 for the development of GDM. [6] Moreover, the new International Association of the
62 Diabetes and Pregnancy Study Groups (IADPSG) criteria, have increased the frequency
63 of GDM by as much as 6 to 11 times [7]. However, the diagnosis and treatment are
64 cost-effective when considering postpartum outcomes for both the mother and the child.
65 [8–10]. The International Federation of Gynecology and Obstetrics (IFGO) proposes
66 different strategies to implement universal screening depending on the resources
67 available in each country. Standard screening in the first trimester includes only fasting
68 glucose; however, it suggests that in high-risk populations, an oral glucose tolerance test

69 (OGTT) with 75 g could be performed at the initial visit, repeating it at 24-28 weeks if
70 the first result is negative. [11] Thus, waiting until that gestational age to initiate treatment
71 could delay a potential improvement in the rate of complications, similar to the preventive
72 action of acetylsalicylic acid to prevent preeclampsia. [12]

73 Recent studies suggest that abnormal, non-diabetic fasting glucose values in early
74 screening impact complications. [13] Both early hyperglycemia and DIP are associated
75 with worse outcomes than GDM diagnosed by standard methods. [14,15] On the other
76 hand, treating GDM identified by IADPSG criteria using OGTT before 22 weeks in
77 pregnant women with at least one risk factor for GDM, has been shown to reduce neonatal
78 outcomes, although it does not affect those related to hypertensive disorders. [16]
79 However, despite the diversity of criteria for GDM, there is no consensus on first-
80 trimester hyperglycemia, with its nomenclature being variable and complicating
81 comparison between regions. [17]

82 In Lima-Peru , a study conducted in a reference center using universal screening between
83 24-28 weeks with IADPSG criteria found a prevalence of 16%. [18] This prevalence,
84 which is close to the global average, could differ if evaluated in primary care health
85 facilities, especially if early OGTT (before 24 weeks) is applied. Therefore, the objective
86 of this study is to determine the prevalence of hyperglycemia during pregnancy in four
87 primary care centers in South Lima at the first contact using OGTT.

88 **Material and Methods**

89 **Study Design and clinical setting**

90 A cross-sectional study was conducted analyzing data from the Gestational Education in
91 Diabetes (GEIDI) program implemented in four maternal and child health centers in
92 South Lima. The GEIDI program is an early diagnosis and educational intervention
93 strategy aimed at pregnant women diagnosed with gestational diabetes through the oral
94 glucose tolerance test (OGTT) during their initial contact. This program was funded by
95 the World Diabetes Foundation (WDF) and executed by a professional and technical team
96 from the Peruvian Juvenile Diabetes Association (ADJ in Spanish) and the María
97 Auxiliadora Hospital. Interventions were carried out at the José Carlos Mariátegui
98 Maternal and Child Center (JCM) in Villa María del Triunfo district, San Genaro
99 Maternal and Child Center (SG) and the Virgen del Carmen Maternal and Child Center
100 (VC) in Chorrillos district and Manuel Barreto Maternal and Child Center (MB) in San
101 Juan de Miraflores district. Pregnant women were recruited from February 2019 to
102 August 2022.

103 **Population, sample and sampling**

104 Pregnant women attended at the four primary care centers, aged 15 years or older, Peruvian
105 nationality, and having resided in the district for more than six months, were included in
106 the study. Fasting glucose screening is part of the procedures of the Ministry of Health in
107 maternal care, but it was applied for the first time in this population through the oral glucose
108 tolerance test (OGTT) using 75 gr of glucose. Patients with known diabetes mellitus prior
109 to pregnancy, uncertain last menstrual period or not confirmed by ultrasound performed
110 before 24 weeks of gestation, and multiple pregnancies were excluded. The sampling

111 method was non-probabilistic census, accepting all pregnant women who met the eligibility
112 criteria based on the provided data.

113 **Variables**

114 Hyperglycemia in Pregnancy: For this study, diabetes in pregnancy was defined as having
115 fasting glucose values greater than 126 mg/dl (7.0 mmol/l) or values greater than 200
116 mg/dl (11.1 mmol/l) at 2 hours, at any gestational age. For gestational diabetes mellitus
117 (GDM), we applied the HAPO criteria, where a diagnosis was positive if fasting glucose
118 was between 92 and 125 mg/dl (5.1 to 6.9 mmol/l) , glucose at 1 hour was greater than
119 180 mg/dl (9.9 mmol/l) , and glucose at 2 hours was between 153 and 199 mg/dl (8.5 to
120 11.0 mmol/l), with at least one positive result being sufficient.

121 Other Variables: Based on the gestational age during the OGTT, the timing of screening
122 was classified as early (24 weeks or less), standard (24-28 weeks), and late (more than 28
123 weeks). The year of the OGTT (2019, 2020, 2021, 2022) and age group (less than 18; 18
124 to 24.9; 25 to 29.9; 30 to 34.9; 35 to 39.9; 40 to 44.9; and 45 or more) were also recorded.

125 **Procedures**

126 The GEIDI program scheduled an Oral Glucose Tolerance Test with 75 g of anhydrous
127 glucose during the first contact of the pregnant woman with the health center, obtaining
128 three venous samples: baseline, at 1 hour, and at 2 hours. Glucose was measured using
129 the glucose oxidase method, employing a Wiener reagent with a coefficient of variation
130 <2%, following standard guidelines for analysis. An online reporting system was
131 established for laboratory results registration. After diagnosis, clinical management was
132 based on the guidelines from the Ministry of Health. Additionally, educational sessions
133 were provided for nutritional management and tools for glycemic self-monitoring were

134 supplied through the donation of glucose meters. Pregnant women were referred to the
135 Hospital María Auxiliadora for evaluation by endocrinology and gynecology if the
136 maternal-infant health centers lacked the necessary specialty or if the patient required
137 evaluation at a higher-level facility.

138 For the study, the authors' team requested the laboratory results data of the screened
139 pregnant women from the GEIDI program coordinators. This information was provided
140 without identifying data such as names or national identity document numbers. Data were
141 evaluated and analyzed from January 15 to March 30, 2024 and included age, date of the
142 OGTT, gestational age, source health center, and the glucose values from the OGTT.

143 **Analysis plan**

144 The health center of origin, age group, gestational age at the time of the oral glucose
145 tolerance test (OGTT), and the type of screening performed were described using absolute
146 and relative frequencies. Additionally, the proportion of altered glycemia, the total
147 number of glucose measurements, and the type of glycemic alteration were calculated.
148 The demographic characteristics of pregnant women were compared based on the timing
149 of screening: early (less than 24 weeks), standard (24-28 weeks), and late (more than 28
150 weeks).

151 Crude and age-adjusted prevalence ratios for the occurrence of GDM or diabetes in
152 pregnancy (DIP) were calculated according to the screening strategy using Poisson
153 regression with robust variances. By the same method, the prevalence ratio for GDM or
154 DIP by age group and year of diagnosis was also calculated. Statistical analysis was
155 performed using Stata version 18.1 (Stata Corp, College Station, Texas, USA), with a
156 significance level set at 0.05 for all hypothesis tests.

157 **Ethical considerations**

158 This protocol was evaluated by the Ethics Committee of the Universidad Peruana
159 Cayetano Heredia, with registration code 200797 and certificate 646-01-21. Patient
160 confidentiality was maintained through the anonymization of records..

161 **Results**

162 The study was conducted from February 2019 to August 2022, with a total of 4,710
163 pregnant women screened. 4,495 met the inclusion and exclusion criteria. From the
164 selected group, 2,590 (57.6%) underwent early screening, 901 (20.0%) standard
165 screening, and 1,004 (22.4%) late screening (**Figure 1**). The restrictions imposed in 2020
166 due to the COVID-19 pandemic led to a decrease in the screening rate; however, this rate
167 recovered in 2021 and 2022.

168

169 **Figure 1. Selection flowchart of the GEIDI Program for the calculation of the**
170 **prevalence of gestational diabetes mellitus**

171 OGTT: Oral Glucose Tolerance Test. DM: Diabetes mellitus

172

173 **General Characteristics**

174 The screened pregnant population was predominantly young, with 78.1% between 18 and
175 35 years. Regarding OGTT results, abnormal fasting glucose levels were found in 539
176 pregnant women (12.0%), representing the highest percentage of altered results.
177 Abnormal glucose levels at 1 hour were identified in 193 women (4.2%), and abnormal
178 glucose levels at 2 hours were found in 97 women (2.1%)

179 Breaking down these findings, it was observed that among the screened pregnant
180 population, only 542 (12.1%) exhibited altered fasting glucose levels, either in isolation
181 or in combination with postprandial glucose levels, and only 127 (2.8%) showed
182 alterations in postprandial glucose levels (**Table 1**).

183

184

185 **Table 1. Characteristics of pregnant women screened**

186

Characterstics	N (%)
Total	4495 (100.0)
Age (years)	
Media DE	
< 18	121 (2.7)
18 – 24.9	1319 (29.3)
25 – 29.9	1245 (27.7)
30 – 34.9	950 (21.1)
35 – 39.9	627 (13.9)
40 – 44.9	213 (4.7)
45 and over	20 (0.4)
Health care facility	
Jose Carlos Mariátegui VMT	2400 (53.4)
Manuel Barreto SJM	343 (7.6)
San Genaro – Chorrillos	1233 (27.4)
Virgen del Carmen –Chorrillos	519 (11.6)
Screening year	
2019	1953 (43.5)
2020	657 (14.6)
2021	1298 (28.9)
2022	587 (13.1)
Screening gestational age	
8 or less	477 (10.6)
9 a 12	723 (16.1)
13 a 16	559 (12.4)
17 a 23	831 (18.5)
24 a 28	898 (19.9)
29 a 32	492 (10.9)
32 a 36	413 (9.2)
37 and over	102 (2.3)
Screening time	
Early	2590 (57.6)
Standard	898 (20.0)
Late	1007 (22.4)

Blood glucose	
Fasting glucose	
Less than 92 mg/dl (5.1 mmol/l)	3956 (88.0)
92 to 125.9 mg/dl (5.1 to 6.9 mmol/l)	520 (11.6)
126 and over (7 mmol/l)	19 (0.4)
Blood glucose at 1 hour	
Less than 180 mg/dl (9.9 mmol/l)	4302 (95.7)
180 and over (10 mmol/l)	193 (4.3)
Blood glucose at 2 hours	
Less than 153 (8.5 mmol/l)	4398 (97.8)
153 to 199.9 mg/dl (8.5 to 11.0 mmol/L)	74 (1.7)
200 and over (11.1 mmol/l)	23 (0.5)
Type of glycemc alteration	
No	3826 (85.1)
Basal only	441 (9.8)
Basal and postprandial	101 (2.3)
Postprandial only(s)	127 (2.8)

187

188 The pregnant women included in the three screening strategies had comparable ages
 189 (p=0.213). The early screening strategy exhibited the highest proportion of altered fasting
 190 glucose, with 13.5%, compared to 9.9% in the standard screening and 9.8% in the late
 191 screening (p=0.010) (**Table 2**).

192

193 **Table 2. Demographic characteristics according to screening strategy in pregnant**
 194 **women.**

195

	Early screening	Standard screening	Late screening	p-value
General	2590	898	1007	
Age (years)				
(Media ± SD)	28.3 ± 6.6	28.1 ± 6.6	28.0 ± 6.4	0.310 ^a
Age group				

< 18	80 (3.1)	15 (1.7)	26 (2.6)	
18 – 24.9	717 (27.7)	291 (32.4)	311 (30.9)	
25 – 29.9	752 (29.0)	244 (27.2)	249 (24.7)	
30 – 34.9	529 (20.4)	169 (18.8)	252 (25.0)	
35 – 39.9	368 (14.2)	129 (14.4)	130 (12.9)	
40 – 44.9	129 (5.0)	46 (5.1)	38 (3.8)	
45 and over	15 (0.6)	4 (0.5)	1 (0.1)	
Health care facility, n(%)				
Jose Carlos Mariátegui VMT	675 (26.1)	344 (38.3)	214 (21.3)	<0.001 ^a
Manuel Barreto SJM	1437 (55.5)	362 (40.3)	601 (59.7)	
San Genaro – Chorrillos	270 (10.4)	125 (13.9)	124 (12.3)	
Virgen del Carmen –Chorrillos	208 (8.0)	67 (7.5)	68 (6.8)	
Screening year, n(%)				
2019	1140 (44.0)	385 (42.9)	428 (42.5)	<0.001 ^a
2020	407 (15.7)	132 (14.7)	118 (11.7)	
2021	668 (25.8)	284 (31.6)	346 (34.4)	
2022	375 (14.5)	97 (10.8)	115 (11.4)	
Fasting glucose , (Media ± SD)				
mg/dl	80.5 ± 13.1	78.5 ±10.0	77.7 ± 11.3	<0.001 ^a
mmol /l	4.51 ± 0.73	4.36 ± 0.56	4.31 ± 0.63	
Blood glucose at 1 hour (Media ± SD)				
mg/dl	120 ± 32.8	119.3 ± 29.9	121.9 ± 29.8	0.161 ^a
mmol /l	6.66 ± 1.82	6.62 ± 1.66	6.77 ± 1.65	
Blood glucose at 2 hours (Media ± SD)				
mg/dl	96.1 ± 24.7	96.7 ± 23.2	95.7 ± 22.7	0.646 ^a
mmol /l	5.33 ± 1.37	5.37 ± 1.29	5.31 ± 1.266	
Fasting glucose category, n (%)				
Less than 92 mg/dl (5.1 mmol/l)	2239 (86.5)	809 (90.1)	908 (90.2)	0.005 ^c
92 to 125.9 mg/dl (5.1 to 6.9 mmol/l)	337 (13.0)	86 (9.6)	97 (9.6)	
126 mg /dl and over (7 mmol/l)	14 (0.5)	3 (0.3)	2 (0.2)	
Blood glucose at 1 hour category, n (%)				
Less than 180 mg/dl (9.9 mmol/l)	2481 (95.8)	857 (95.0)	964 (96.1)	0.901 ^b
180 mg/dl and over (10 mmol/l)	109 (4.2)	41 (4.6)	43 (4.3)	
Blood glucose at 2 hours category, n (%)				
Less than 153 mg/dl (8.5 mmol/l)	2534 (97.8)	874 (97.3)	990 (98.3)	0.338 ^c
153 to 199.9 mg/dl (8.5 to 11.0 mmol/L)	40 (1.5)	21 (2.3)	13 (1.3)	

200 mg/dl and over (11.1 mmol/l)	16 (0.6)	3 (0.3)	4 (0.4)	
Type of glycemiac alteration, n (%)				
No	2167 (83.7)	779 (86.6)	880 (87.4)	0.007 b
Basal only	294 (11.4)	69 (7.7)	78 (7.8)	
Basal and postprandial	60 (2.3)	20 (2.2)	21 (2.1)	
Postprandial only(s)	69 (2.7)	30 (3.3)	28 (2.8)	

196

197 VMT_villa María del Triunfo. SJM: San Juan de Miraflores ^a Anova One way ^b Pearson chi square test ^c Fisher exact test

198

199 Prevalence of Hyperglycemia in Pregnancy

200 A general prevalence of hyperglycemia in pregnancy was found to be 14.9% (95% CI
 201 13.9 -15.9), with gestational diabetes mellitus (GDM) at 14.2% (95% CI 13.2 - 15.3) and
 202 diabetes in pregnancy at 0.7% (95% CI 0.5 - 0.9). Of these cases, 95.5% corresponded to
 203 GDM (60.2% identified before 24 weeks and 35.3% after 24 weeks), while 4.5%
 204 presented with diabetes in pregnancy (**Table 3**).

205

206 **Table 3. Prevalence of hyperglycemia in pregnancy of screened pregnant women**
 207 **in four centers in South Lima.**

Tipo de hiperglicemia en embarazo	Prevalence ^a n (%)	CI 95%	Prevalence ^b %	CI 95%
No	3826 (85.1)			
Hiperglicemia in pregnancy	669 (14.9)	(IC95% 13.9 -15.9)	100%	
Gestational diabetes	639 (14.2)	(IC95% 13.2 – 15.3)	95.5%	(IC95% 93.7 – 96.9)
Early GDM	403 (8.9)	(IC95% 8.1 – 9.8)	60.2%	(IC95% 56.4 – 63.9t)
Standard GDM	113 (2.5)	(IC95% 2.1 – 3.0)	16.9%	(IC95% 14.1 -19.9))
Late GDM	123 (2.7)	(IC95% 2.2 – 3.2)	18.4%	(IC95% 15.5 – 21.5)
Diabetes in pregnancy	30 (0.7)	(IC95% 0.5 - 0.9).	4.5%	(IC95% 3.0 – 6.3)
Early DIP	20 (0.4)	(IC95% 0.2 – 0.6)	3.0%	(IC95% 1.8 – 4.5)
Standard DIP	6 (0.1)	(IC95% 0.05 – 0.3)	0.9%	(IC95% 0.3 – 1.9)
Late DIP	4 (0.1)	(IC95% 0.02 – 0.2)	0.6%	(IC95% 0.1 – 1.5)

208

GDM: Gestational diabetes DIP: Diabetes n pregnancy

209 ^a taking as a denominator the total of 4495 pregnant women. ^b Taking as a denominator the totality of 669 pregnant women with
 210 HIP
 211 According to the timing of the screening, early showed a higher frequency of gestational
 212 diabetes at 26%, compared to standard (PR 1.26; 95% CI 1.01 – 1.51; p=0.035) (**Table**
 213 **4**). Tables S2 and S3 provide a description of the patients with GDM and DIP,
 214 respectively.

215 **Table 4. Prevalence ratios of glycemic results according to type of screening**

	n /N	Prevalence (CI 95%)	Crude	p-value	Ajusted*	p-value
Gestational diabetes						
Early screening ^a	403 / 2570	15.7 (14.3 – 17.1)	1.23 (1.01 -1.50)	0.031	1.23 (1.01 – 1.49)	0.036
Standard screening ^b	113 / 892	12.7 (10.6 – 15.0)	1.00		1.00	
Late screening ^c	123 / 1003	12.3 (10.3 – 14.5)	0.96 (0.76 – 1.22)	0.790	0.97 (0.76 – 1.23)	0.820
Diabetes in pregnancy						
Early screening ^a	20/2590	0.77 (0.47 – 1.19)	1.15 (0.46 – 2.86)	0.755	1.13 (0.46 – 2.80)	0.790
Standard screening ^b	6 / 898	0.67 (0.25 – 1.45)	1.00		1.00	
Late screening ^c	4 /1007	0.39 (0.11 – 1.01)	0.59 (0.17 – 2.10)	0.419	0.62 (0.17 – 2.23)	0.474

216 PRc: Crude prevalence ratio. RPa: Adjusted prevalence ratio.

217 * Age adjusted. ^a Before 24 weeks. ^b Between 24 -28 weeks. ^c After 28 weeks

218

219

220 **Hyperglycemia before 24 weeks**

221 When the OGTT was performed before 24 weeks (early screening), the prevalence of
 222 GDM in 2020 showed a decrease of 34% compared to 2019. Subsequently increased a
 223 45% in 2021 and a 92% in 2022. Regarding diabetes in pregnancy (DIP), no significant
 224 differences were observed among the years. Additionally,
 225 A progressive increase in GDM was evident with advancing age, starting from 30 years.
 226 This trend was statistically significant only in the age group of 30 to 40 years (**Table 5**).

227

228 **Hyperglycemia after 24 weeks**

229 For the OGTT conducted between 24 and 28 weeks (standard screening), the prevalence
230 of GDM decreased in 2020, followed by increases of 24% and an astonishing 102% in
231 2021 and 2022, respectively. On the other hand, when the OGTT was performed after 28
232 weeks (late screening), a higher increase in prevalence was observed, with increases of
233 62% and 130% for the same years. In standard screening, it was notable that the age group
234 of 30 to 35 years exhibited a 75% increase in prevalence (PR 1.75; 95% CI 1.1-2.76;
235 $p=0.032$) (**Table 5**).

236

237

238 **Table 5. Prevalence ratios of glycemic results according to year, health center and age group of each screening strategy.**

239

	Early screening			Standard screening			Late screening		
	Prevalence	PR (CI 95%)	p-value	Prevalence	PR (CI 95%)	p-value	Prevalence	PR (CI 95%)	p-value
Gestational diabetes									
Screening year									
2019	12.3 (139 /1134)	1.00		12.3 (43/384)	1.00		9.8 (42/428)	1.00	
2020	9.4 (38/ 404)	0.76 (0.54 – 1.08)	0.127	3.4 (9/132)	0.61 (0.31 – 1.21)	0.012	7.7 (9/117)	0.78 (0.39 – 1.56)	0.594
2021	19.4 (128/ 659)	1.58 (1.27 – 1.97)	<0.001	15.3 (39/279)	1.24 (0.83 – 1.87)	0.283	16.0 (55/344)	1.62 (1.09 – 2.39)	0.015
2022	26.7 (98/ 373)	2.14 (1.70 – 2.69)	<0.001	16.5 (22/97)	2.02 (1.27 – 3.21)	0.003	14.9 (17/114)	2.30 (1.41 – 3.76)	0.001
Age group									
< 18 años	8.8 (7/ 80)	0.64 (0.31 – 1.34)	0.242	6.7 (1/ 15)	0.64 (0.09 – 4.37)	0.655	7.7 (2/ 26)	0.81 (0.20 – 3.19)	0.747
18 – 24.9	13.6 (97/716)	1.00		10.3 (30/290)	1.00		9.5 (30/311)	1.00	
25 – 29.9	13.9 (104/747)	1.02 (0.79 – 1.32)	0.835	11.9 (29/244)	1.00 (0.61 – 1.64)	0.572	12.2 (27/249)	1.12 (0.69 – 1.83)	0.642
30 – 34.9	17.9 (94/523)	1.32 (1.02 – 1.72)	0.033	17.4 (29/167)	1.75 (1.11 – 2.76)	0.032	14.3 (38/252)	1.56 (0.99 – 2.44)	0.051
35 – 39.9	20.6 (75/364)	1.52 (1.15 – 1.99)	0.003	15.9 (20/126)	1.58 (0.93 – 2.68)	0.111	14.5 (19/127)	1.55 (0.91 – 2.65)	0.109
40 – 44.9	17.6 (22/115)	1.29 (0.85 – 1.98)	0.224	6.5 (3/ 46)	0.63 (0.20 – 1.98)	0.430	11.9 (7/ 37)	1.96 (0.92 – 4.14)	0.078
45 a más	27.7 (4/ 15)	1.96 (0.83 – 4.64)	0.123	25 (1/ 4)	2.41 (0.42 – 13.7)	0.318	0.0 (0/ 1)	NC	NC
Diabetes in pregnancy*									
Screening year									
2019	0.5 (6/1140)	1.00		0.3 (1/385)	1.00		0.0 (0/428)	NC	

2020	0.7 (3/ 407)	1.40 (0.35 – 5.57)	0.633	0.0 (0/132)	NC		0.8 (1/118)	NC
2021	1.4 (9/ 668)	2.56 (0.91 – 7.16)	0.073	2.9 (5/284)	6.78 (0.79 – 57.9)	0.080	0.6 (2/346)	NC
2022	0.5 (2/ 375)	1.01 (0.20 – 5.00)	0.987	0.8 (0/ 97)	NC		0.0 (1/115)	NC
Age group								
< 18 años	0.0 (0/ 80)	NC		0.0 (0/ 15)	NC		0.0 (0/ 26)	NC
18 – 24.9	0.1 (1/717)	1.00		0.3 (1/291)	1.00		0.0 (0/311)	NC
25 – 29.9	0.6 (5/752)	4.76 (0.55 – 40.7)	0.154	0.0 (0/244)	NC		0.0 (0/249)	NC
30 – 34.9	1.0 (6/529)	8.13 (0.98 – 67.4)	0.052	1.1 (2/169)	3.44 (0.31 – 36.9)	0.311	0.0 (0/252)	NC
35 – 39.9	1.2 (4/368)	7.79 (0.87 – 69.5)	0.066	3.4 (3/129)	6.76 (0.70 – 88.8)	0.096	1.5 (3/130)	NC
40 – 44.9	2.6 (4/129)	22.2 (2.54 – 197.5)	0.005	0.0 (0/ 46)	NC		2.3 (1/ 38)	NC
45 a más	0.0 (0/ 15)	NC		0.0 (0/ 4)	NC		0.0 (0/ 1)	NC

240

*NO diabetes in pregnancy was the union of euglycemia and gestational diabetes

241

242 **Discusión**

243 Hyperglycemia in pregnancy is a condition that significantly impacts maternal and
244 perinatal outcomes, and its screening in primary care is essential. In this study, we found
245 that approximately 1 in 7 pregnant women (14.9%) presents this condition, excluding
246 those with known diabetes prior to pregnancy. Of these cases, 95.5% corresponded to
247 gestational diabetes mellitus (GDM), with 60.2% identified before 24 weeks and 35.3%
248 after this period; additionally, 4.5% presented diabetes in pregnancy.

249 The global prevalence of subtypes of hyperglycemia in pregnancy varies according to the
250 specific type and geographic region. According to the medical literature, hyperglycemia
251 in pregnancy affects approximately 16.9% of live births worldwide. Within this group, it
252 is estimated that 16.0% of cases are attributed to diabetes in pregnancy, which includes
253 both known diabetes and previously undiagnosed cases.[19] Regarding gestational
254 diabetes, it is estimated to affect approximately 14% of pregnancies worldwide, although
255 this figure can vary depending on risk factors and diagnostic methods used.[20] For
256 instance, in Australia, the prevalence of hyperglycemia in pregnancy was reported at
257 13.1%, with 12.7% attributed to gestational diabetes and 0.4% to diabetes in
258 pregnancy.[21] The study by Cosson et al. provides data on the prevalence of different
259 subtypes of hyperglycemia in pregnancy, reporting 10.8% for early diagnosed gestational
260 diabetes and 11.7% for later diagnosed gestational diabetes, while diabetes in pregnancy
261 and early diagnosed diabetes have a prevalence of 0.6% each.[15] Furthermore, a
262 systematic review aimed at comparing the prevalence of GDM according to the new
263 IADPSG criteria versus the previous WHO criteria found that early screening increased
264 prevalence by 60% and standard screening by 78%.[22] It is important to highlight that
265 more than 90% of cases of hyperglycemia during pregnancy occur in low- and middle-

266 income countries, underscoring the relevance of this condition from a public health and
267 maternal-infant health perspective, particularly in developing countries.[19]

268

269 **Explanation of Results**

270 Several institutions agree that pregnant women with risk factors for diabetes should
271 undergo early screening due to the high associated complication rates.[23] The IADPSG
272 guidelines, adopted by the WHO in 2013, recommended using the same cut-off points
273 between 24-28 weeks at any time during pregnancy.[24] However, it is crucial to
274 differentiate between two conditions that may be detected during early screening:
275 diabetes in pregnancy (pre-gestational) and other lesser hyperglycemic states that might
276 later qualify as GDM but could merely be transient hyperglycemia during the first
277 trimester.

278 In 2015, an IADPSG panel suggested that fasting glucose values between 92 and 125
279 mg/dl should not be used for early screening, although they did not offer clear
280 alternatives.[25] This recommendation was based on an Italian study showing that only
281 45% of patients with fasting glucose greater than 92 mg/dl during the first trimester were
282 positive in the OGTT between 24-28 weeks, with an area under the curve (AUROC) of
283 0.614. [26] Similarly, a study in China recommended using a cut-off of 110 mg/dl instead
284 of 92 mg/dl for the first trimester, showing a slight but consistent decline in fasting
285 glucose from the first to the second trimester across the entire cohort.[27] In Simmons'
286 clinical trial, only 67% of pregnant women with early GDM tested positive again in the
287 OGTT at 24 weeks. [16] However, a fasting glucose level greater than 92 mg/dl may be
288 considered a risk factor for the subsequent development of GDM, similar to
289 pregestational body mass index.

290 The main goal of screening is early detection to reduce the burden of subsequent disease,
291 and not merely to diagnose prematurely without effects on relevant clinical outcomes. It
292 has been documented that early GDM is associated with a higher risk of perinatal
293 mortality, neonatal hypoglycemia, and increased insulin use compared to standard
294 screening.[28] Nevertheless, it remains unclear whether the treatment of early gestational
295 diabetes and its intensive management can be applied to all pregnant women or only those
296 with certain risk factors.[29,30]

297 This group of "early GDM" may represent a different range of phenotypes compared to
298 those diagnosed after 24 weeks. A study comparing early GDM (before week 21) with
299 late GDM (from week 24 onwards) found lower insulin sensitivity in the early GDM
300 group, with similar beta cell dysfunction. However, the early screening group presented
301 a higher pregestational body mass index (BMI).[31] It is important to discuss the impact
302 of COVID-19, which appeared in the second year of recruitment, leading to a decrease in
303 screening tests. However, when conditions improved, the program continued to follow
304 the same algorithm, resulting in a notable increase in the prevalence of hyperglycemia,
305 reaching up to 60% compared to 2019. Other studies have reported an increase ranging
306 from 14% to 34%. [32,33] A possible explanation for this increase could be related to the
307 rise in pregestational weight and gestational weight gain, which is linked to lifestyle
308 changes such as reduced physical activity and increased stress, as well as changes in
309 healthcare access and service utilization.[34–36]

310 **Research Recommendations**

311 Longitudinal studies or cost-effectiveness analyses are needed to evaluate the impact on
312 perinatal outcomes for patients diagnosed with early gestational diabetes (GDM) or
313 through standard screening to determine whether this trend is also observed in Latino
314 populations. Furthermore, greater clarity is needed on whether early screening could be

315 implemented universally or based on risk factors (such as obesity or previous history of
316 GDM). It is essential to define the exact timing during the first trimester, considering the
317 physiological changes in pregnant women (before or after 16 weeks) or to use less strict
318 diagnostic glycemic thresholds (recommended 110 mg/dl fasting). Regarding the
319 diagnostic method, the oral glucose tolerance test (OGTT) and its variants are universally
320 accepted. However, they are not easily applied in logistical terms for screening.
321 Alternative diagnostic methods are being explored that offer better feasibility, such as
322 hemoglobin A1c with a cut-off of 5.9%.[37] Additionally, multiple biological markers,
323 such as C-reactive protein, adiponectin, and tumor necrosis factor, are being evaluated
324 either in isolation or in combination with clinical variables as alternatives to the
325 OGTT.[38]

326 **Limitations and Strengths**

327 Several limitations were identified in the present study. The cut-off points used for early
328 gestational diabetes (GDM) lack long-term studies to support their impact and are based
329 on IADPSG criteria. This may lead to an overestimation of GDM prevalence.
330 Nonetheless, the World Health Organization (WHO) continues to recommend their use.
331 Furthermore, the database did not include other variables that could explain differences
332 in diagnostic prevalence, such as pregestational body mass index or previous history of
333 gestational diabetes. However, we have sufficient statistical power to estimate differences
334 between age groups. The COVID-19 pandemic also affected data collection and the
335 performance of tests. Nevertheless, the tests that were conducted adhered to strict
336 biosafety protocols. It is possible that GDM between 24 and 28 weeks is
337 underrepresented, as the OGTT was not repeated for patients who tested negative in the
338 early screening. Among the strengths of this study, we highlight the sample size, which

339 allows for prevalence estimates with an accuracy of 1.3%. Additionally, the OGTT was
340 used, recognized as the gold standard for diagnosing gestational diabetes.

341

342 **Conclusion**

343 In pregnant women from four primary care centers in South Lima, it was found that one
344 in seven (14.9%) presented hyperglycemia in pregnancy. GDM was 14.2%, and DIP was
345 0.7%. Early screening showed the highest proportion of GDM compared to standard or
346 late screening. No differences in the prevalence of diabetes in pregnancy were found
347 between the groups. Longitudinal studies are needed to determine whether this higher
348 prevalence associated with early screening has repercussions on maternal-perinatal
349 complications and whether it requires any form of treatment.

350 Bibliographic references

- 351
352 1. International Diabetes Federation. IDF Diabetes Atlas 10th edition. Bruselas, Bélgica.;
353 2021. Available: [https://diabetesatlas.org/idfawp/resource-](https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf)
354 [files/2021/07/IDF_Atlas_10th_Edition_2021.pdf](https://diabetesatlas.org/idfawp/resource-files/2021/07/IDF_Atlas_10th_Edition_2021.pdf)
- 355 2. Farrar D, Simmonds M, Bryant M, Sheldon TA, Tuffnell D, Golder S, et al.
356 Hyperglycaemia and risk of adverse perinatal outcomes : systematic review and meta-
357 analysis. *BMJ*. 2016;354: i4694. doi:10.1136/bmj.i4694
- 358 3. Poolsup N, Suksomboon N, Amin M. Effect of Treatment of Gestational Diabetes
359 Mellitus : A Systematic Review and Meta-Analysis. *PLoS One*. 2014;9: 1–9.
360 doi:10.1371/journal.pone.0092485
- 361 4. Ferrara A. Increasing Prevalence of Gestational Diabetes Mellitus. A public health
362 perspective. *Diabetes Care*. 2007;30: S141-146. doi:10.2337/dc07-s206
- 363 5. Instituto Nacional de Estadística e Informática. “Perú: Encuesta Demográfica y de Salud
364 Familiar 2023 - Nacional y Departamental. Lima, Perú; 2024. Available:
365 [https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_](https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib1950/libro.pdf)
366 [digitales/Est/Lib1950/libro.pdf](https://www.inei.gob.pe/media/MenuRecursivo/publicaciones_digitales/Est/Lib1950/libro.pdf)
- 367 6. Thangaratinam S, Rogozińska E, Jolly K, Glinkowski S, Duda W, Borowiack E, et al.
368 Interventions to reduce or prevent obesity in pregnant women : a systematic review.
369 *Health Technol Assess (Rockv)*. 2012;16. doi:10.3310/hta16310
- 370 7. Behboudi-Gandevani S, Amiri M, Yarandi RB, Tehrani FR. The impact of diagnostic
371 criteria for gestational diabetes on its prevalence : a systematic review and meta -
372 analysis. *Diabetol Metab Syndr*. 2019;11: 11. doi:10.1186/s13098-019-0406-1
- 373 8. Chen PY, Finkelstein EA, Ng MJ, Yap F, Yeo GSH, Rajadurai VS, et al. Incremental
374 Cost-Effectiveness Analysis of Gestational Diabetes Mellitus Screening Strategies in
375 Singapore. *Asia Pac J Public Health*. 2016;28: 15–25. doi:10.1177/1010539515612908
- 376 9. Werner E, Pettker C, Zuckerwise L, Reel M, Funai E, Henderson J, et al. Screening for
377 Gestational Diabetes Mellitus: Are the Criteria Proposed by the International Association
378 of the Diabetes and Pregnancy Study Groups Cost-Effective? *Diabetes Care*. 2012;35:
379 529–35. doi:10.2337/dc11-1643
- 380 10. Duran A, Sáenz S, Torrejón MJ, Bordí U E, Del Valle L, Galindo M, et al. Introduction
381 of IADPSG criteria for the screening and diagnosis of gestational diabetes mellitus
382 results in improved pregnancy outcomes at a lower cost in a large cohort of pregnant
383 women: The St. Carlos gestationaldiabetes study. *Diabetes Care*. 2014;37: 2442–2450.
384 doi:10.2337/dc14-0179
- 385 11. Hod M, Kapur A, Sacks D, Hadar E, Agarwal M, Di Renzo G, et al. The International
386 Federation of Gynecology and Obstetrics (FIGO) Initiative on gestational diabetes

- 387 mellitus: A pragmatic guide for diagnosis, management, and care. *Int J Gynecol Obstet.*
388 2015;131: S173-211. doi:10.1016/S0020-7292(15)30033-3
- 389 12. Roberge S, Nicolaidis K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin
390 dose on the prevention of preeclampsia and fetal growth restriction: systematic review
391 and meta-analysis. *Am J Obstet Gynecol.* 2017;216: 110-120.e6.
392 doi:10.1016/J.AJOG.2016.09.076
- 393 13. Ye Y, Xiong Y, Zhou Q, Xiao X, Li X. Early-Pregnancy Intermediate Hyperglycemia
394 and Adverse Pregnancy Outcomes Among Women Without Gestational Diabetes. *J Clin*
395 *Endocrinol Metab.* 2021;107: e1541. doi:10.1210/CLINEM/DGAB841
- 396 14. Regnault N, Lebreton E, Tang L, Fosse-Edorh S, Barry Y, Olié V, et al. Maternal and
397 neonatal outcomes according to the timing of diagnosis of hyperglycaemia in pregnancy:
398 a nationwide cross-sectional study of 695,912 deliveries in France in 2018. *Diabetologia.*
399 2024;67: 516–527. doi:10.1007/S00125-023-06066-4
- 400 15. Cosson E, Bentounes SA, Nachetergaele C, Berkane N, Pinto S, Sal M, et al. Prognosis
401 Associated with Sub-Types of Hyperglycaemia in Pregnancy. *J Clin Med.* 2021;10.
402 doi:10.3390/JCM10173904
- 403 16. Simmons D, Immanuel J, Hague WM, Teede H, Nolan CJ, Peek MJ, et al. Treatment of
404 Gestational Diabetes Mellitus Diagnosed Early in Pregnancy. *New England Journal of*
405 *Medicine.* 2023;388: 2132–2144.
406 doi:10.1056/NEJMOA2214956/SUPPL_FILE/NEJMOA2214956_DATA-
407 SHARING.PDF
- 408 17. Agarwal MM, Dhatt GS, Othman Y. Gestational diabetes: differences between the
409 current international diagnostic criteria and implications of switching to IADPSG. *J*
410 *Diabetes Complications.* 2015;29: 544–549. doi:10.1016/J.JDIACOMP.2015.03.006
- 411 18. Larrabure-Torrealva GT, Martinez S, Luque-Fernandez MA, Sanchez SE, Mascaro PA,
412 Ingar H, et al. Prevalence and risk factors of gestational diabetes mellitus : findings from
413 a universal screening feasibility program in Lima , Peru. *BMC Pregnancy Childbirth.*
414 2018;18: 303. doi:<https://doi.org/10.1186/s12884-018-1904-0>
- 415 19. Guariguata L, Linnenkamp U, Beagley J, Whiting DR, Cho NH. Global estimates of the
416 prevalence of hyperglycaemia in pregnancy. *Diabetes Res Clin Pract.* 2014;103: 176–
417 185. doi:10.1016/J.DIABRES.2013.11.003
- 418 20. Sweeting A, Hannah W, Backman H, Catalano P, Feghali M, Herman WH, et al.
419 Epidemiology and management of gestational diabetes. *Lancet.* 2024;404: 175–192.
420 doi:10.1016/S0140-6736(24)00825-0
- 421 21. Moses RG, Wong VCK, Lambert K, Morris GJ, San Gil F. The prevalence of
422 hyperglycaemia in pregnancy in Australia. *Aust N Z J Obstet Gynaecol.* 2016;56: 341–
423 345. doi:10.1111/AJO.12447
- 424 22. Saeedi M, Cao Y, Fadhil H, Gustafson H, Simmons D. Increasing prevalence of
425 gestational diabetes mellitus when implementing the IADPSG criteria: A systematic

- 426 review and meta-analysis. *Diabetes Res Clin Pract.* 2021;172: 108642.
427 doi:10.1016/J.DIABRES.2020.108642
- 428 23. Malaza N, Masete M, Adam S, Dias S, Nyawo T, Pheiffer C. A Systematic Review to
429 Compare Adverse Pregnancy Outcomes in Women with Pregestational Diabetes and
430 Gestational Diabetes. *Int J Environ Res Public Health.* 2022;19: 10846.
431 doi:10.3390/IJERPH191710846/S1
- 432 24. Organización Panamericana de la Salud. Criterios diagnósticos y clasificación de la
433 hiperglucemia detectada por primera vez en el embarazo. 2016; 6. Available:
434 <https://iris.paho.org/handle/10665.2/27870>
- 435 25. McIntyre HD, Sacks DA, Barbour LA, Feig DS, Catalano PM, Damm P, et al. Issues
436 With the Diagnosis and Classification of Hyperglycemia in Early Pregnancy. *Diabetes*
437 *Care.* 2016;39: 53–54. doi:10.2337/DC15-1887
- 438 26. Corrado F, D’Anna R, Cannata ML, Interdonato ML, Pintaudi B, Di Benedetto A.
439 Correspondence between first-trimester fasting glycaemia, and oral glucose tolerance
440 test in gestational diabetes diagnosis. *Diabetes Metab.* 2012;38: 458–461.
441 doi:10.1016/J.DIABET.2012.03.006
- 442 27. Zhu WW, Yang HX, Wei YM, Yan J, Wang ZL, Li XL, et al. Evaluation of the Value of
443 Fasting Plasma Glucose in the First Prenatal Visit to Diagnose Gestational Diabetes
444 Mellitus in China. *Diabetes Care.* 2013;36: 586. doi:10.2337/DC12-1157
- 445 28. Immanuel J, Simmons D. Screening and Treatment for Early-Onset Gestational Diabetes
446 Mellitus: a Systematic Review and Meta-analysis. *Curr Diab Rep.* 2017;17.
447 doi:10.1007/S11892-017-0943-7
- 448 29. Falavigna M, Schmidt MI, Trujillo J, Alves LF, Wendland ER, Torloni MR, et al.
449 Effectiveness of gestational diabetes treatment: A systematic review with quality of
450 evidence assessment. *Diabetes Res Clin Pract.* 2012;98: 396–405.
451 doi:10.1016/j.diabres.2012.09.002
- 452 30. Behboudi-Gandevani S, Bidhendi-Yarandi R, Panahi MH, Vaismoradi M. The Effect of
453 Mild Gestational Diabetes Mellitus Treatment on Adverse Pregnancy Outcomes: A
454 Systemic Review and Meta-Analysis. *Front Endocrinol (Lausanne).* 2021;12: 640004.
455 doi:10.3389/FENDO.2021.640004/BIBTEX
- 456 31. Bozkurt L, Göbl CS, Pfligl L, Leitner K, Bancher-Todesca D, Luger A, et al.
457 Pathophysiological Characteristics and Effects of Obesity in Women With Early and
458 Late Manifestation of Gestational Diabetes Diagnosed by the International Association
459 of Diabetes and Pregnancy Study Groups Criteria. *J Clin Endocrinol Metab.* 2015;100:
460 1113–1120. doi:10.1210/JC.2014-4055
- 461 32. Auger N, Wei SQ, Dayan N, Ukah U V., Quach C, Lewin A, et al. Impact of Covid-19
462 on rates of gestational diabetes in a North American pandemic epicenter. *Acta Diabetol.*
463 2023;60: 257–264. doi:10.1007/S00592-022-02000-Z

- 464 33. Zanardo V, Tortora D, Sandri A, Severino L, Mesirca P, Straface G. COVID-19
465 pandemic: Impact on gestational diabetes mellitus prevalence. *Diabetes Res Clin Pract.*
466 2022;183. doi:10.1016/j.diabres.2021.109149
- 467 34. Rhou YJJ, Elhindi J, Melov SJ, Cheung NW, Pasupathy D. Indirect effects of the
468 COVID-19 pandemic on risk of gestational diabetes and factors contributing to increased
469 risk in a multiethnic population: a retrospective cohort study. *BMC Pregnancy*
470 *Childbirth.* 2023;23: 1–10. doi:10.1186/S12884-023-05659-6/TABLES/4
- 471 35. Nour TY, Altıntaş KH. Effect of the COVID-19 pandemic on obesity and its risk
472 factors: a systematic review. *BMC Public Health.* 2023;23: 1–24. doi:10.1186/S12889-
473 023-15833-2/FIGURES/1
- 474 36. Pinedo-Soria A, Pasco-Ramírez F, Samir Cubas W. Ganancia de peso durante el
475 confinamiento por la COVID-19 en la población peruana. *Revista Médica Herediana.*
476 2022;33: 72–73. doi:10.20453/RMH.V33I1.4172
- 477 37. Hughes RCE, Moore MP, Gullam JE, Mohamed K, Rowan J. An Early Pregnancy
478 HbA1c $\geq 5.9\%$ (41 mmol/mol) Is Optimal for Detecting Diabetes and Identifies Women
479 at Increased Risk of Adverse Pregnancy Outcomes. *Diabetes Care.* 2014;37: 2953–2959.
480 doi:10.2337/DC14-1312
- 481 38. Huhn EA, Rossi SW, Hoesli I, Göbl CS. Controversies in Screening and Diagnostic
482 Criteria for Gestational Diabetes in Early and Late Pregnancy. *Front Endocrinol*
483 *(Lausanne).* 2018;9: 411579. doi:10.3389/FENDO.2018.00696/BIBTEX
- 484
- 485

486 **Supplementary tables**


487

488 **Table S1. Results of basal glycemia, 60 minutes and 120 minutes of OGTT according**
489 **to clinical characteristics in pregnant women**

490 **Table S2. Characteristics of patients with gestational diabetes**

491

492 **Tabla S3. Características de las pacientes con Diabetes pregestacional.**



Figure